How much revenue did Talkmed Group generate this year?
Talkmed Group has achieved a revenue of 67.03 M SGD this year.
Talkmed Group Revenue 2024
Talkmed Group Revenue
67.03 M SGD
Ticker
5G3.SI
ISIN
SG2G61000003
In 2024, Talkmed Group's sales reached 67.03 M SGD, a -20.01% difference from the 83.79 M SGD sales recorded in the previous year.
The Talkmed Group Revenue history
| YEAR | REVENUE (undefined SGD) | GROSS MARGIN (%) |
|---|---|---|
| 2024e | 67.03 | 70,06 |
| 2023 | 83.79 | 56,04 |
| 2022 | 76.6 | 61,31 |
| 2021 | 60.75 | 57,12 |
| 2020 | 62.14 | 75,58 |
| 2019 | 75.92 | 61,86 |
| 2018 | 61.28 | 76,63 |
| 2017 | 61.36 | 76,53 |
| 2016 | 68.91 | 68,14 |
| 2015 | 65.72 | 71,46 |
| 2014 | 63.17 | 74,34 |
| 2013 | 56.27 | 83,45 |
| 2012 | 51.86 | 90,55 |
| 2011 | 49.14 | 95,56 |
| 2010 | 48.34 | 97,15 |
Talkmed Group Revenue, EBIT, Net Income SG2G61000003 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Talkmed Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Talkmed Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Talkmed Group’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Talkmed Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Talkmed Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Talkmed Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Talkmed Group’s growth potential.
Talkmed Group Revenue, EBIT and net profit per share
| Date | Talkmed Group Revenue | Talkmed Group EBIT | Talkmed Group Net Income |
|---|---|---|---|
| 2024e | 67.03 M undefined | 0 undefined | 0 undefined |
| 2023 | 83.79 M undefined | 39.04 M undefined | 32.18 M undefined |
| 2022 | 76.6 M undefined | 39.21 M undefined | 30.55 M undefined |
| 2021 | 60.75 M undefined | 26.94 M undefined | 25.12 M undefined |
| 2020 | 62.14 M undefined | 27.32 M undefined | 22.77 M undefined |
| 2019 | 75.92 M undefined | 41.21 M undefined | 35.75 M undefined |
| 2018 | 61.28 M undefined | 34.16 M undefined | 28.91 M undefined |
| 2017 | 61.36 M undefined | 39.6 M undefined | 32.04 M undefined |
| 2016 | 68.91 M undefined | 48.39 M undefined | 37.39 M undefined |
| 2015 | 65.72 M undefined | 47.94 M undefined | 37.33 M undefined |
| 2014 | 63.17 M undefined | 46.45 M undefined | 38.53 M undefined |
| 2013 | 56.27 M undefined | 35.81 M undefined | 28.21 M undefined |
| 2012 | 51.86 M undefined | 38.49 M undefined | 31.98 M undefined |
| 2011 | 49.14 M undefined | 39.23 M undefined | 32.6 M undefined |
| 2010 | 48.34 M undefined | 39.01 M undefined | 32.43 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2010 | 48.34 M SGD | 39.01 M SGD | 32.43 M SGD |
| 2011 | 49.14 M SGD | 39.23 M SGD | 32.6 M SGD |
| 2012 | 51.86 M SGD | 38.49 M SGD | 31.98 M SGD |
| 2013 | 56.27 M SGD | 35.81 M SGD | 28.21 M SGD |
| 2014 | 63.17 M SGD | 46.45 M SGD | 38.53 M SGD |
| 2015 | 65.72 M SGD | 47.94 M SGD | 37.33 M SGD |
| 2016 | 68.91 M SGD | 48.39 M SGD | 37.39 M SGD |
| 2017 | 61.36 M SGD | 39.6 M SGD | 32.04 M SGD |
| 2018 | 61.28 M SGD | 34.16 M SGD | 28.91 M SGD |
| 2019 | 75.92 M SGD | 41.21 M SGD | 35.75 M SGD |
| 2020 | 62.14 M SGD | 27.32 M SGD | 22.77 M SGD |
| 2021 | 60.75 M SGD | 26.94 M SGD | 25.12 M SGD |
| 2022 | 76.6 M SGD | 39.21 M SGD | 30.55 M SGD |
| 2023 | 83.79 M SGD | 39.04 M SGD | 32.18 M SGD |
| 2024e | 67.03 M SGD | 0 SGD | 0 SGD |
Talkmed Group stock margins SG2G61000003 ·
The Talkmed Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Talkmed Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Talkmed Group.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Talkmed Group's sales revenue. A higher gross margin percentage indicates that the Talkmed Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Talkmed Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Talkmed Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Talkmed Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Talkmed Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Talkmed Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Talkmed Group Margin History
| Talkmed Group Gross margin | Talkmed Group Profit margin | Talkmed Group EBIT margin | Talkmed Group Profit margin |
|---|---|---|---|
| 2024e | 61.31 % | 0 % | 0 % |
| 2023 | 61.31 % | 46.59 % | 38.4 % |
| 2022 | 61.31 % | 51.18 % | 39.88 % |
| 2021 | 57.12 % | 44.34 % | 41.34 % |
| 2020 | 61.31 % | 43.97 % | 36.64 % |
| 2019 | 61.31 % | 54.29 % | 47.09 % |
| 2018 | 61.31 % | 55.74 % | 47.18 % |
| 2017 | 61.31 % | 64.54 % | 52.21 % |
| 2016 | 61.31 % | 70.21 % | 54.26 % |
| 2015 | 61.31 % | 72.94 % | 56.81 % |
| 2014 | 61.31 % | 73.54 % | 61 % |
| 2013 | 61.31 % | 63.64 % | 50.13 % |
| 2012 | 61.31 % | 74.22 % | 61.67 % |
| 2011 | 61.31 % | 79.83 % | 66.34 % |
| 2010 | 61.31 % | 80.7 % | 67.09 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2010 | 61.31 % | 80.7 % | 67.09 % |
| 2011 | 61.31 % | 79.83 % | 66.34 % |
| 2012 | 61.31 % | 74.22 % | 61.67 % |
| 2013 | 61.31 % | 63.64 % | 50.13 % |
| 2014 | 61.31 % | 73.54 % | 61 % |
| 2015 | 61.31 % | 72.94 % | 56.81 % |
| 2016 | 61.31 % | 70.21 % | 54.26 % |
| 2017 | 61.31 % | 64.54 % | 52.21 % |
| 2018 | 61.31 % | 55.74 % | 47.18 % |
| 2019 | 61.31 % | 54.29 % | 47.09 % |
| 2020 | 61.31 % | 43.97 % | 36.64 % |
| 2021 | 57.12 % | 44.34 % | 41.34 % |
| 2022 | 61.31 % | 51.18 % | 39.88 % |
| 2023 | 61.31 % | 46.59 % | 38.4 % |
| 2024e | 61.31 % | 0 % | 0 % |
Talkmed Group Aktienanalyse
What does Talkmed Group do?
Talkmed Group Ltd. is a leading healthcare company in Asia specializing in the development, manufacturing, and marketing of innovative diagnostic and therapeutic solutions in oncology. The company was founded in 2002 by Dr. Ang Peng Tiam, with a focus on providing high-quality cancer treatments. Since its inception, Talkmed Group Ltd. has become a pioneer in cancer research and treatment in Asia and has grown to become one of the largest providers of cancer treatments in the region. The company's business model is centered around offering high-quality diagnostic solutions and innovative cancer therapies to provide better patient care. They work closely with pharmaceutical companies to develop and market innovative medications and therapies that contribute to higher survival rates and improved quality of life for cancer patients. In addition, Talkmed Group Ltd. is involved in the development of medical diagnostic and monitoring devices tailored to the needs of cancer patients. They offer a range of treatments and programs that aim to provide accessible, affordable, and high-quality care for cancer patients. Overall, Talkmed Group Ltd. is an innovative company dedicated to improving the lives of cancer patients through the development, manufacturing, and marketing of diagnostic and therapeutic solutions in oncology. Talkmed Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Talkmed Group's Sales Figures
The sales figures of Talkmed Group originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Talkmed Group’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Talkmed Group's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Talkmed Group’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Talkmed Group stock
How much was the turnover of the company Talkmed Group compared to the previous year?
The revenue of Talkmed Group has increased by -20.01% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Talkmed Group?
The revenue of Talkmed Group is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Talkmed Group measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Talkmed Group so important for investors?
The revenue of Talkmed Group is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Talkmed Group pay?
Over the past 12 months, Talkmed Group paid a dividend of 0.02 SGD . This corresponds to a dividend yield of about 5.52 %. For the coming 12 months, Talkmed Group is expected to pay a dividend of 0.02 SGD.
What is the dividend yield of Talkmed Group?
The current dividend yield of Talkmed Group is 5.52 %.
When does Talkmed Group pay dividends?
Talkmed Group pays a quarterly dividend. This is distributed in the months of May, September, May, September.
How secure is the dividend of Talkmed Group?
Talkmed Group paid dividends every year for the past 11 years.
What is the dividend of Talkmed Group?
For the upcoming 12 months, dividends amounting to 0.02 SGD are expected. This corresponds to a dividend yield of 5.52 %.
In which sector is Talkmed Group located?
Talkmed Group is assigned to the 'Health' sector.
Wann musste ich die Aktien von Talkmed Group kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Talkmed Group from 8/22/2024 amounting to 0.014 SGD, you needed to have the stock in your portfolio before the ex-date on 8/14/2024.
When did Talkmed Group pay the last dividend?
The last dividend was paid out on 8/22/2024.
What was the dividend of Talkmed Group in the year 2023?
In the year 2023, Talkmed Group distributed 0.024 SGD as dividends.
In which currency does Talkmed Group pay out the dividend?
The dividends of Talkmed Group are distributed in SGD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Talkmed Group
Our stock analysis for Talkmed Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Talkmed Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Talkmed Group Revenue
- Talkmed Group Net Income
- Talkmed Group P/E
- Talkmed Group P/S
- Talkmed Group EBIT
- Talkmed Group Dividend
- Talkmed Group Stocks
- Talkmed Group Market capitalization
- Talkmed Group Debt
- Talkmed Group Liabilities
- Talkmed Group Equity
- Talkmed Group AAQS
- Talkmed Group Employees
- Talkmed Group ROE
- Talkmed Group ROA
- Talkmed Group ROCE
